David Chen

1 month ago | onlinelibrary.wiley.com | David Chen

Introduction As climate change has become a global emergency, studying decarbonisation and energy transition policies in major carbon-emitting and energy-consuming countries has become increasingly important. This paper focuses on climate and energy transition in China and its state-led project of ecological civilisation (hereafter eco-civilisation) in particular. The concept of eco-civilisation was introduced as an official ideology and brought to public attention in 2006.

2 months ago | onlinelibrary.wiley.com | Andrea Migone |David Chen |Bryan Evans |Alex Howlett

1 Introduction: Interest Group Policy Advocacy and Corporate Contract Lobbying Lobbying is a multi-faceted phenomenon where various actors contact government officials and decision-makers to promote their policy preferences. Much of the now long-standing literature on the subject (Chari 2024) deals with interest group advocacy behavior and studies how such groups seek to have governments adopt their views of policy problems and potential solutions for them (Baumgartner et al.

Nov 13, 2024 | mondaq.com | David Chen |Huiya Wu |Kristopher Brown |Krystal J. Lin

Goodwin is presenting a two-part publication series covering life sciences trends involving license deals, M&A, and financing for Greater China's life sciences sector. See the first post in the series here. While the overall Chinese M&A market fluctuated from 2021 to 2023 due to the pandemic and other factors, the life sciences pharmaceutical and biotech market remained relatively stable. Though the number of deals dipped in 2022, in 2023, it quickly recovered to 2021 levels.

Mar 19, 2024 | mondaq.com | David Chen |Huiya Wu |Yoko Bian

An in-depth look at trends involving licensing deals in a year that saw a significant increase in out-licensing and particularly in-licensing activity in China. This is the first of two articles focused on 2023 life sciences deals in China. The second article, which is coming soon, looks at trends in M&A. In 2023, there were 240 reported life sciences licensing deals in China, an increase of almost 50% compared to 2021.

Mar 14, 2024 | jdsupra.com | Yoko Bian |Summer Lawson |David Chen

This is the first of two articles focused on 2023 life sciences deals in China. The second article, which is coming soon, looks at trends in M&A. In 2023, there were 240 reported life sciences licensing deals in China, an increase of almost 50% compared to 2021.